Results 141 to 150 of about 230,556 (169)

Role of genetics and epigenetics in Graves' orbitopathy. [PDF]

Eur Thyroid J
Marinò M, Rotondo Dottore G, Menconi F, Comi S, Cosentino G, Rocchi R, Latrofa F, Figus M, Santini F.   +8 more
europepmc   +1 more source

Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves' orbitopathy. [PDF]

Front Endocrinol (Lausanne)
Boutzios G, Nikolopoulou A, Chatzi S, Tzioufas AG, Goules AV.   +4 more
europepmc   +1 more source

Effects of pulse glucocorticoid treatment on retinal blood flow in patients with active Graves' orbitopathy. [PDF]

BMC Ophthalmol
Mohammadi H, Güneş İB, Arı Ş.
europepmc   +1 more source

Role of the suppressor of cytokine signaling-3 in the pathogenesis of Graves' orbitopathy. [PDF]

Front Endocrinol (Lausanne)
Kim W, Seo MK, Kim YJ, Choi SH, Ku CR, Kim S, Lee EJ, Yoon JS.   +7 more
europepmc   +1 more source

A randomized controlled trial on the effect of hydroxychloroquine in mild Graves' orbitopathy (GO-HCQ): study protocol. [PDF]

Trials
Lin CH, Wei YH, Lu JY, Li HY, Lee CW, Yang CY, Chang CH, Wu WC, Wang CY, Shih SR.   +9 more
europepmc   +1 more source

MMP14 as a central mediator of TGF-β1-induced extracellular matrix remodeling in graves' orbitopathy. [PDF]

Front Endocrinol (Lausanne)
Wang X, Lu J, He Y, Shu Q, Lin Y, Su W, Wang P.   +6 more
europepmc   +1 more source

Statin Use and the Risk of Developing Graves' Orbitopathy in Patients With Graves' Disease: A Systematic Review and Meta-Analysis With Regional and Gender-Stratified Analyses. [PDF]

Cureus
Kermaj M, Hakkeem B, Fero H, Doddapaneni VK, Ylli A.   +4 more
europepmc   +1 more source

Natural history of graves’ orbitopathy after treatment

Endocrine, 2016
Intravenous glucocorticoids are used for Graves’ orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery).
Claudio Marcocci, Paolo Vitti, Michele Marinò   +2 more
exaly   +2 more sources